Merck Oncology Data Presentations at 2015 ASCO Annual Meeting

Abstracts involving Merck Oncology studies at this year’s 2015 ASCO Annual Meeting are listed below. Embargoed abstracts and abstracts from investigator-initiated / investigator-sponsored studies are not included in this document.

KEYTRUDA (pembrolizumab)

Head and Neck Cancer

- **EMBARGOED - (Abstract #LBA6008) Late-Breaker Presentation:** Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. T. Seiwert. Monday, June 1, 3:39 PM – 3:51 PM CDT. Location: S100bc. ASCO Press Program, Friday, May 29, 1:00 PM CDT.


- **(Abstract #TPS3094) Poster:** KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. S. Powell. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.


Melanoma

- **(Abstract #3000) Oral Presentation:** Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. J. Wolchok. Monday, June 1, 1:15 PM – 1:27 PM CDT. Location: S406.


- **(Abstract #3009) Poster Discussion:** Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. M. Atkins. Saturday, May 30, 8:00 AM – 11:30 AM CDT (poster session). Location: S Hall A. 3:00 PM – 4:15 PM CDT (discussion). Location: S406.

- **(Abstract #3012) Poster Discussion:** Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). I. Puzanov. Saturday, May 30, 8:00 AM – 11:30 AM CDT (poster session). Location: S Hall A. 3:00 PM – 4:15 PM CDT (discussion). Location: S406.

- **(Abstract #9009) Poster Discussion:** Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. H. Kluger. Monday, June 1, 1:15 PM – 4:45 PM CDT (poster session). Location: S Hall A. 4:45 PM – 6:00 PM CDT (discussion). Location: S100bc.*
- **(Abstract #9010) Poster Discussion:** The use of pembrolizumab for the treatment of metastatic uveal melanoma. L. Kottschade. Monday, June 1, 1:15 PM – 4:45 PM CDT (poster session). Location: S Hall A. 4:45 PM – 6:00 PM CDT (discussion). Location: S100bc.*

- **(Abstract #9013) Poster Discussion:** Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). R. Dronca. Monday, June 1, 1:15 PM – 4:45 PM CDT (poster session). Location: S Hall A. 4:45 PM – 6:00 PM CDT (discussion). Location: S100bc.*

- **(Abstract #3027) Poster:** TCR use and cytokine response in PD-1 blockade. J. Zaretsky. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.*

- **(Abstract #3058) Poster:** Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. T. Gangadhar. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

- **(Abstract #3068) Poster:** Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. R. Joseph. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

- **(Abstract #9031) Poster:** Clinical characteristics predictive of response to pembrolizumab in advanced melanoma. K. Tsai. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*

- **(Abstract #9040) Poster:** Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). D. Schadendorf. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.

- **(Abstract #9050) Poster:** Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. C. Robert. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.

- **(Abstract #9073) Poster:** Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM). M. Kibiro. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*

- **(Abstract #9075) Poster:** Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab. R. Munhoz. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*

- **(Abstract #TPS9081) Poster:** A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. A. Ribas. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*

- **(Abstract #TPS9085) Poster:** SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. K. Grossman. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*

**Lung Cancer**


- **(Abstract #8026) Poster:** Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. N. Rizvi. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

- **(Abstract #8031) Poster:** Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. V. Papadimitrakopoulou. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

- **(Abstract #8035) Poster:** Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. S. Goldberg. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.*
• (Abstract #11065P) Poster: Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC). M. Dolled-Filhart. Sunday, May 31, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

• (Abstract #TPS8103) Poster: KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). J. Brahmer. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

• (Abstract #TPS8105) Poster: Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC). T. Mok. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

Gastrointestinal Cancers

• EMBARGOED - (Abstract #LBA100) Late-Breaker Presentation: PD-1 blockade in tumors with mismatch repair deficiency. D. Le. Saturday, May 30, 8:05 AM – 8:17 AM CDT. Location: E Hall D1. ASCO Press Program, Friday, May 29, 1:00 PM CDT.


• (Abstract #3026) Poster: Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). V. Shankaran. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

• (Abstract #TPS3098) Poster: A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer. M. Katz. Saturday, May 30, 8:00 AM – 11:30 AM CDT. Location: S Hall A.

• (Abstract #TPS4135) Poster: Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. C. Fuchs. Monday, June 1, 8:00 AM – 11:30AM CDT. Location: S Hall A.

Bladder Cancer


• (Abstract #TPS4572) Poster: KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. D. Bajorin. Monday, June 1, 1:15 PM – 4:45PM CDT. Location: S Hall A.

• (Abstract #TPS4571) Poster: KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. J. Bellmunt. Monday, June 1, 1:15 PM – 4:45PM CDT. Location: S Hall A.

Ovarian Cancer


Additional Cancers

• (Abstract #TPS10578) Poster: SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. M. Burgess. Sunday, May 31, 8:00 AM – 11:30 AM CDT. Location: S Hall A.*
**EMEND (aprepitant / fosaprepitant dimeglumine)**


- **(Abstract #9598)** Poster: Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. K. Matsumoto. Saturday, May 30, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*


**OTHER MERCK ONCOLOGY MEDICINES**

- **(Abstract #2012)** Poster: Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). V. Puduvalli. Monday, June 1, 1:15 PM – 4:45 PM CDT. Location: S Hall A.*


- **(Abstract #3569)** Poster: Phase I study of preoperative chemoradiation with temozolomide and capecitabine in patients with locally advanced rectal cancer. Y. Hong. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.*

**MERCK ONCOLOGY PIPELINE CANIDATES**

- **(Abstract #10564)** Poster: A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. A. Wagner. Sunday, May 31, 8:00 AM – 11:30 AM CDT. Location: S Hall A.


- **(Abstract #4119)** Poster: SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer. V. Chung. Monday, June 1, 8:00 AM – 11:30 AM CDT. Location: S Hall A.*

*For more information including a complete list of abstract titles, please visit the ASCO website at [https://iplanner.asco.org/AM2015](https://iplanner.asco.org/AM2015).

For additional information on Merck Oncology, visit [http://www.mercknewsroom.com/oncology-infocenter](http://www.mercknewsroom.com/oncology-infocenter).

*Investigator-initiated / investigator-sponsored study; abstracts not included in this document*